Company intelligence / Profile preview

LookMeds

Ownership: Private
Development stage: Commercial

Overview

LookMeds operates as a patient management platform that connects patients with independent physicians and practitioners for access to compounded weight loss medications such as semaglutide and tirzepatide. The company does not develop drugs but facilitates affordable access to these therapies through compounding pharmacy partners. It provides education about the benefits, costs, and regulatory status of compounded GLP-1 agonists for obesity and diabetes[1][2][3][4][8].

Therapeutic areas: Endocrinology
Modalities: Small molecule (e.g., semaglutide, tirzepatide)Peptide (semaglutide is a synthetic peptide)
Industry: Biomedical IT and Biomedical Data Platforms

Drug pipeline

2 assets

semaglutide

Commercial

Indications: Obesity, Type 2 diabetes

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on LookMeds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LookMeds.

Explore the full profile